MELBOURNE, Australia, December 5, 2013 /PRNewswire/ --
Results from the global Diabetes Attitudes, Wishes and Needs 2 study (DAWN2(TM))
presented today at a symposium during the World Diabetes Congress of the
International Diabetes Federation (IDF), show that only 29% of people with
diabetes report that their healthcare team ask for their input when making their
treatment plans. Furthermore, only 33% said they were encouraged by their
healthcare professional to ask questions in the consultation.
These results are surprising, given the importance of active involvement of
people with diabetes in their own treatment and care. In fact, 84% of healthcare
professionals who took part in the study said it would be helpful if their
patients prepared questions in advance of the consultation.
To view the Multimedia News Release, please click:
"People with diabetes who feel supported and capable of self-managing their
condition are more likely to have a successful treatment outcome and therefore
have the opportunity to live a better life with diabetes," explained Ingrid
Willaing, head of Education Research at the Steno Diabetes Center and lead
national investigator for DAWN2(TM) in Denmark, during her symposium
presentation. "The DAWN2(TM) study highlights that far too few people with
diabetes are supported to take an active role".
To help break down communication barriers and misconceptions about diabetes
treatments and thereby improve effective self-management of type 2 diabetes,a
theatre play called "Getting Straight to the Point" was held at the Congress on
4 December. Here, a panel of leading diabetes experts called for both healthcare
professionals and people with type 2 diabetes to create opportunities for open
dialogue, shared decision-making and active engagement for better physical and
A series of other global DAWN2(TM) results were announced during the Congress
highlighting the insufficiencies relating to quality of life with diabetes,
support for families, access to diabetes education and psychosocial support,
positive awareness of diabetes in society and attention to the special needs of
vulnerable populations with diabetes.
"The DAWN2(TM) study calls for united efforts across stakeholders and nations to
advance a person-centredapproach to improve prevention, care, education and
support for people with diabetes and their families," says Sir Michael Hirst,
president of the International Diabetes Federation.
DAWN2(TM) represents the voices of more than 15,000 people with diabetes, their
family members and healthcare professionals in 17 countries across 4 continents.
DAWN2(TM) is a global Novo Nordisk initiative conducted in collaboration with
the IDF, the International Alliance of Patients' Organizations (IAPO), the Steno
Diabetes Center and a range of other national, regional and global partners. The
DAWN2(TM) results highlight opportunities for improving diabetes care, education
and community support by putting people with diabetes and their families centre
stage. The DAWN2(TM) study will be used internationally and nationally to
facilitate dialogue among patient organisations, healthcare professionals and
other key stakeholders to develop action plans for improvement of the lives of
people with diabetes. Further information is available at
About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 90
years of innovation and leadership in diabetes care. The company also has
leading positions within haemophilia care, growth hormone therapy and hormone
replacement therapy. Novo Nordisk employs approximately 37,000 employees in 75
countries, and markets its products in more than 180 countries. For more
information, visit novonordisk.com.
Further information<br /> <br /> Media:<br /> Daniel Vamosi Martinussen<br />
+45-3079-1879<br /> email@example.com<br /> <br /> Ken Inchausti (US)<br />
+1-609-514-8316<br /> firstname.lastname@example.org<br /> <br /> Investors:<br /> Kasper
Roseeuw Poulsen<br /> +45-4442-4303<br /> email@example.com<br /> <br />
Frank Daniel Mersebach<br /> +45-4442-0604<br /> firstname.lastname@example.org<br /> <br
/> Daniel Bohsen<br /> +45-3079-6376<br /> email@example.com<br /> <br />
Lars Borup Jacobsen<br /> +45-3075-3479<br /> firstname.lastname@example.org
<br /> Jannick Lindegaard (US)<br /> +1-609-786-4575<br /> email@example.com
1. I. Willaing, DAWN2(TM) Study Results: Involvement and Education. Oral
Lecture, DAWN2(TM) Symposium, 5 December 2013, World Diabetes Congress of the
International Diabetes Federation (IDF).
r /> <br />
SOURCE Novo Nordisk, DAWN2TM, International Diabetes Federation, Steno Diabetes